LENZ Therapeutics, Inc. Expected to Post Q3 2024 Earnings of ($0.45) Per Share (NASDAQ:LENZ)

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Analysts at Leerink Partnrs cut their Q3 2024 earnings estimates for LENZ Therapeutics in a research report issued on Wednesday, August 14th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings of ($0.45) per share for the quarter, down from their prior estimate of ($0.32). The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($3.06) per share. Leerink Partnrs also issued estimates for LENZ Therapeutics’ Q4 2024 earnings at ($0.52) EPS, FY2024 earnings at ($4.90) EPS, FY2025 earnings at ($3.00) EPS, FY2026 earnings at ($2.10) EPS, FY2027 earnings at ($0.20) EPS and FY2028 earnings at ($2.00) EPS.

LENZ has been the topic of a number of other reports. Piper Sandler reissued an “overweight” rating and set a $36.00 target price on shares of LENZ Therapeutics in a research report on Thursday. HC Wainwright started coverage on shares of LENZ Therapeutics in a research report on Monday, August 12th. They set a “buy” rating and a $38.00 target price on the stock. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $35.00.

LENZ Therapeutics Stock Performance

NASDAQ LENZ opened at $22.75 on Monday. The stock’s fifty day moving average price is $20.73. LENZ Therapeutics has a 52 week low of $14.07 and a 52 week high of $29.82.

Institutional Trading of LENZ Therapeutics

Several institutional investors have recently added to or reduced their stakes in LENZ. BML Capital Management LLC acquired a new stake in LENZ Therapeutics in the first quarter valued at $1,427,000. BNP Paribas Financial Markets acquired a new stake in LENZ Therapeutics in the first quarter valued at $362,000. Jennison Associates LLC acquired a new stake in LENZ Therapeutics in the first quarter valued at $3,009,000. Marquette Asset Management LLC acquired a new stake in LENZ Therapeutics in the first quarter valued at $131,000. Finally, Vanguard Group Inc. acquired a new stake in LENZ Therapeutics in the first quarter valued at $4,621,000. 54.32% of the stock is owned by institutional investors and hedge funds.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.